Journal article

Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia

Caitlin E McOmish, Geoff Pavey, Andrew Gibbons, Shaun Hopper, Madhara Udawela, Elizabeth Scarr, Brian Dean



INTRODUCTION: The glutamatergic system has recently been implicated in the pathogenesis and treatment of major depressive disorders(MDD) and mGlu2/3 receptors play an important role in regulating glutamatergic tone. We therefore measured cortical levels of mGlu2/3 to determine if they were changed in MDD. METHODS: Binding parameters for [(3)H]LY341495 (mGlu2/3 antagonist) were determined to allow optimized in situ binding with autoradiography to be completed using a number of CNS regions. Subsequently, density of [(3)H]LY341495 binding was measured in BA24(anterior cingulate cortex), BA17(visual cortex) and BA46(dorsolateral prefrontal cortex) from subjects with MDD, Bipolar Disorder(BPD), S..

View full abstract


Awarded by NHMRC

Awarded by ARC future fellowship

Funding Acknowledgements

CEM is supported by an NHMRC overseas biomedical research fellowship, a Brain and Behavior Research Foundation young investigator award, and received funding to present these findings from the CASS foundation. BD is an NHMRC Senior Research Fellow (APP1002240). This work was supported in part by NHMRC project grants (APP1045619, APP628699 and APP1066144), the Victorian Government's Operational Infrastructure Support and the Rebecca Cooper Medical Research Foundation. ES was supported by an ARC future fellowship (FT100100689).